Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI)

Trial Profile

Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI)

Completed
Phase of Trial: Phase II/III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Azathioprine (Primary) ; Cyclophosphamide (Primary) ; Rituximab (Primary) ; Glucocorticoids
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Microscopic polyangiitis; Wegener's granulomatosis
  • Focus Therapeutic Use
  • Acronyms RAVE
  • Most Recent Events

    • 17 Jun 2017 Results evaluating the determinants of rituximab (n=88) in patients from this study presented at the 18th Annual Congress of the European League Against Rheumatism
    • 28 Nov 2013 New trial record
    • 30 Oct 2013 Results assessing efficacy of open-label rituximab in patients with a severe disease flare between 6-18 months presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top